Jump to content
Sclero Forums
Joelf

CCL2 in the Circulation Predicts Long-Term Progression of Interstitial Lung Disease (ILD) in Patients With Early Systemic Sclerosis (SSc).

Recommended Posts

CCL2 in the Circulation Predicts Long-Term Progression of Interstitial Lung Disease (ILD) in Patients With Early Systemic Sclerosis (SSc).

 

Higher CCL2 levels in the circulation were predictive of ILD progression and poorer survival in patients with early SSc, which support the notion that CCL2 has a role as a biomarker and potential therapeutic target. PubMed, Arthritis Rheumatol, 2017 Sep;69(9):1871-1878. (Also see Pulmonary Fibrosis)

 

This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.


Jo Frowde

ISN Board Member

ISN Secretary of the Board

ISN Assistant Webmaster

SD World Webmaster

ISN Sclero Forums Manager

ISN News Manager

ISN Hotline Support Specialist

International Scleroderma Network (ISN)

Share this post


Link to post
Share on other sites

Interesting study that may pave the way for targeting the biomarker.  I wonder how many of us have ever had our CCL2 measured.

 

I do read a fair bit about all the research that has gone into gene therapy and other promising treatments and wonder who the lucky few who benefit are and how they are chosen.

 

 

Share this post


Link to post
Share on other sites

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.

Guest
Reply to this topic...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.


×
×
  • Create New...